{"product_id":"macrogenics-pestle-analysis","title":"MacroGenics PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how political shifts, regulatory pressures, economic trends, and rapid biotech innovation are shaping MacroGenics’s strategic outlook—our concise PESTLE highlights key external risks and opportunities you can act on today. Purchase the full analysis for a detailed, ready-to-use report that equips investors, advisors, and strategists with the insights needed to forecast risks, spot growth avenues, and strengthen decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug pricing legislation impacts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Inflation Reduction Act's drug-pricing provisions continue to shape MacroGenics' strategy; projected Medicare price negotiations for top biologics by 2026 threaten margins on high-revenue oncology assets, pushing conservative long-term revenue models (analysts cut peak sales estimates by 10–25% for comparable biologics). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA regulatory environment shifts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePolitical leadership at the FDA directly shapes approval timelines and clinical rigor; under 2025 policies the agency granted 72 accelerated approvals since 2018, favoring life-threatening disease therapies, which benefits antibody-based programs like MacroGenics.\u003c\/p\u003e\n\u003cp\u003eContinued emphasis on accelerated pathways represents a material tailwind as MacroGenics’ lead candidates rely on expedited review to reach market faster and extend revenue runway.\u003c\/p\u003e\n\u003cp\u003eMacroGenics must align trials with evolving guidance on surrogate endpoints—given FDA’s increased post-marketing demands (40% of accelerated approvals required additional confirmatory studies in 2023)—to avoid label restrictions or withdrawals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical supply chain stability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGlobal trade tensions and instability in regions like Taiwan and the South China Sea risk disrupting supplies of reagents and lab components, with 2024 semiconductor and specialty chemical export restrictions affecting ~18% of biotech input chains.\u003c\/p\u003e\n\u003cp\u003eMacroGenics depends on an international network for R\u0026amp;D and projected commercial production, sourcing over 40% of critical reagents from Asia as of 2025.\u003c\/p\u003e\n\u003cp\u003eUS policy pushes to reshore biotech manufacturing could raise COGS by an estimated 10–20% but would reduce supply disruption risk and improve long-term security for clinical and commercial supply chains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment R\u0026amp;D funding and tax credits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFederal R\u0026amp;D grants and tax credits remain crucial for mid-cap biopharma; NIH awarded over $45 billion in FY2024, sustaining non-dilutive funding that companies like MacroGenics rely on for antibody discovery and platform work.\u003c\/p\u003e\n\u003cp\u003eShifts in congressional healthcare priorities could reduce such support—proposed FY2025 NIH adjustments and changing tax code debates risk limiting grant and R\u0026amp;D credit availability.\u003c\/p\u003e\n\u003cp\u003eMacroGenics has leveraged these frameworks to defray early-stage costs, historically using government funding alongside partnerships to reduce cash burn and capital raises.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNIH funding \u0026gt; $45B in FY2024\u003c\/li\u003e\n\u003cli\u003eFY2025 budget debates threaten grant stability\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D tax credits aid in offsetting antibody discovery costs\u003c\/li\u003e\n\u003cli\u003eMacroGenics uses grants\/credits to lower dilution and cash burn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal healthcare policy harmonization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs MacroGenics scales international trials, alignment of regulatory standards is critical; divergent US, EU, and Asian policies can add months to approval timelines and raise compliance costs—estimated industry-wide harmonization could cut trial duplication by up to 20% per WHO\/ICH analyses (2024).\u003c\/p\u003e\n\u003cp\u003eThe company actively tracks ICH discussions and related political debates to reduce approval delays and averted costs, given MacroGenics held $414.6M cash and equivalents at 2024 year-end to support global development and potential regulatory-driven expenditures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegulatory divergence increases administrative burden and compliance spend\u003c\/li\u003e\n\u003cli\u003eICH harmonization could reduce duplicate trials ~20% per 2024 analyses\u003c\/li\u003e\n\u003cli\u003eMacroGenics cash reserves $414.6M (2024) to absorb global regulatory costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMacroGenics: NIH cash cushion vs drug-price cuts, Asia supply risk, approval uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedicare drug-price negotiations (IRAct) threaten peak biologic margins (analyst cuts 10–25%); FDA accelerated pathways favor MacroGenics’ antibody programs but 40% of such approvals in 2023 required confirmatory studies; 40%+ reagents sourced from Asia (2025) risks supply shocks amid trade tensions; NIH funding \u0026gt;$45B (FY2024) and MacroGenics cash $414.6M (2024) buffer regulatory\/commercial risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH funding FY2024\u003c\/td\u003e\n\u003ctd\u003e$45B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMacroGenics cash (2024)\u003c\/td\u003e\n\u003ctd\u003e$414.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents from Asia (2025)\u003c\/td\u003e\n\u003ctd\u003e40%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst peak-sales cut\u003c\/td\u003e\n\u003ctd\u003e10–25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccelerated approvals needing confirmatory studies (2023)\u003c\/td\u003e\n\u003ctd\u003e40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how Political, Economic, Social, Technological, Environmental, and Legal factors uniquely influence MacroGenics, with each category expanded into detailed, business-specific subpoints and forward-looking insights to support scenario planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise, visually segmented PESTLE summary of MacroGenics to drop directly into presentations or strategy packs, easing cross-team alignment and supporting focused discussions on external risks and market positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital market volatility and funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCapital market volatility heavily influences MacroGenics ability to raise equity; biotech IPO and secondary issuance volume fell ~22% in 2024 versus 2023, cooling investor sentiment toward early-stage assets.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, rate swings kept 10-year U.S. Treasury yields around 3.8–4.2%, raising cost of debt and reducing institutional appetite for high-risk biotech allocations.\u003c\/p\u003e\n\u003cp\u003eMacroGenics must preserve cash runway and a debt-to-equity ratio below industry median (~0.6 in 2024) to withstand market contractions when liquidity tightens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary pressures on R\u0026amp;D costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePersistent inflation—US CPI running near 3.4% year-over-year in 2025—raises costs for specialized R\u0026amp;D labor, lab equipment (up 6–8% in biotech supply chains 2024–25) and CRO\/clinical management fees, compressing MacroGenics’ cash runway and increasing need for financing; fiscal 2024 R\u0026amp;D spend was $244M, highlighting exposure.\u003c\/p\u003e\n\u003cp\u003eMacroGenics mitigates this by optimizing its proprietary DART bispecific platform to reduce candidate attrition and trial timelines, improving per-program capital efficiency and lowering marginal cost per lead selection.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare provider reimbursement trends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEconomic pressure on healthcare systems—global health spending growth slowed to about 3.8% in 2023–24—drives tighter reimbursement from public and private payers, raising evidence thresholds for coverage decisions.\u003c\/p\u003e\n\u003cp\u003eWith bispecifics often priced between $150,000–$300,000 per patient annually, MacroGenics must prove superior cost-effectiveness versus SOC to gain favorable formulary placement.\u003c\/p\u003e\n\u003cp\u003eHealth technology assessment bodies like NICE and ICER increasingly hinge decisions on cost per QALY; ICER’s 2024 cost-effectiveness benchmarks remain a critical gate for oncology market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency exchange rate fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAs MacroGenics expands partnerships and international trials, foreign exchange risk rises; a 10% USD appreciation in 2024 would lower reported non-US milestone receipts and inflate overseas R\u0026amp;D costs, given ~25% of trial sites outside the US.\u003c\/p\u003e\n\u003cp\u003eIn 2025 MacroGenics could face volatility: FX moved ~8–12% among major pairs (USD\/EUR, USD\/GBP), so hedging and multi-currency invoicing reduce earnings-per-share sensitivity and protect cash runway.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExposure: ~25% operations outside US\u003c\/li\u003e\n\u003cli\u003eFX volatility 2024–25: ~8–12% in major pairs\u003c\/li\u003e\n\u003cli\u003eImpact: USD strength reduces reported milestones, raises foreign expenses\u003c\/li\u003e\n\u003cli\u003eMitigation: hedging, multi-currency invoicing, geographic diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic partnership and M\u0026amp;A activity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe 2025 patent-cliff pressure on Big Pharma—Pfizer, Roche and Novartis facing combined patent expiries reducing revenues by an estimated $40–60bn through 2026—heightens M\u0026amp;A\/licensing appetite, making MacroGenics’ DART platform a high-value target for bolt-on innovation.\u003c\/p\u003e\n\u003cp\u003eMacroGenics can capture partnering deals as large pharma deploys \u0026gt;$120bn annual R\u0026amp;D budgets and $200–300bn in cash on balance sheets to replenish pipelines, positioning the company as an attractive collaborator or acquisition candidate.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstimated Big Pharma R\u0026amp;D \u0026gt;$120bn (2025)\u003c\/li\u003e\n\u003cli\u003eCash reserves among top 10 pharma ~$250bn (2025)\u003c\/li\u003e\n\u003cli\u003eProjected revenue gaps from patent cliffs $40–60bn (2025–26)\u003c\/li\u003e\n\u003cli\u003eDART platform = strategic, high-acquisition appeal\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiotech funding down 22% as rates, inflation and FX bite; Big Pharma M\u0026amp;A war chest surges\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCapital markets cooled: biotech IPO\/secondary volume down ~22% in 2024; 10y UST ~3.8–4.2% in 2025 raising cost of debt. US CPI ~3.4% Y\/Y (2025) and biotech supply inflation 6–8% cut cash runway; fiscal 2024 R\u0026amp;D $244M. FX volatility 8–12% (2024–25) with ~25% ops outside US; Big Pharma R\u0026amp;D \u0026gt;$120B and cash ~250B (2025) boosting M\u0026amp;A demand for DART.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech funding change 2024\u003c\/td\u003e\n\u003ctd\u003e-22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10y UST (2025)\u003c\/td\u003e\n\u003ctd\u003e3.8–4.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS CPI (2025)\u003c\/td\u003e\n\u003ctd\u003e~3.4%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend (2024)\u003c\/td\u003e\n\u003ctd\u003e$244M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX vol (2024–25)\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOps outside US\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig Pharma R\u0026amp;D (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$120B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig Pharma cash (top10, 2025)\u003c\/td\u003e\n\u003ctd\u003e~$250B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eMacroGenics PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact MacroGenics PESTLE Analysis document you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751782658425,"sku":"macrogenics-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/macrogenics-pestle-analysis.png?v=1772234613","url":"https:\/\/growthsharematrix.com\/products\/macrogenics-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}